Ficus hirta Vahl. ameliorates liver fibrosis by triggering hepatic stellate cell ferroptosis through GSH/GPX4 pathway

被引:1
|
作者
Yang, Yuxuan [1 ,2 ]
Chen, Yanchun [1 ,2 ]
Feng, Dongge [1 ,2 ]
Wu, Huixing [3 ]
Long, Changrui [3 ]
Zhang, Jianping [1 ,2 ]
Wang, Jinghao
Zhou, Benjie [4 ]
Li, Shasha [1 ]
Xiang, Shijian [4 ,5 ]
机构
[1] Jinan Univ, Affiliated Hosp 1, Dept Pharm, Guangzhou 510632, Peoples R China
[2] Jinan Univ, Sch Pharm, Guangzhou 510632, Peoples R China
[3] Guangdong Med Univ, Sch Pharm, Dongguan 523808, Peoples R China
[4] Sun Yat Sen Univ, Affiliated Hosp 7, Dept Pharm, Shenzhen 518107, Peoples R China
[5] Shenzhen Key Lab Chinese Med Act Subst Screening &, Shenzhen 518107, Peoples R China
关键词
Ficus hirta vahl; Liver fibrosis; GSH/GPX4; pathway; Apigenin; MOLECULAR-MECHANISMS;
D O I
10.1016/j.jep.2024.118557
中图分类号
Q94 [植物学];
学科分类号
071001 ;
摘要
Ethnopharmacological relevance: Ficus hirta Vahl., a traditional Chinese medicine commonly used in the Lingnan region, has been extensively used for liver disease treatment in China. Its notable antioxidant and antiinflammatory properties have been reported in previous studies. However, its potential effect and underlying mechanism on liver fibrosis remains unclear. Aim of study: This study was aimed to investigate the effect and its underlying mechanism of Ficus hirta Vahl on liver fibrosis in vitro and in vivo. Materials and methods: The main components of Ficus hirta Vahl in blood were investigated by using UPLC-Q/ TOF-MS/MS. Two animal models of liver fibrosis, the CCl4 and MCD induced mice, were used to assess the efficacy of Ficus hirta Vahl on liver fibrosis. Metabolomics was used to detect the level of metabolites in the serum of liver fibrosis mice after Ficus hirta Vahl treatment. Furthermore, the mechanism was validated in vitro using the human liver stellate cell line LX-2. The binding affinities of the active ingredients of Ficus hirta Vahl to the main targets of liver fibrosis were also determined. Finally, we identified the key active ingredients responsible for the treatment of liver fibrosis in vivo. Results: Fibrosis and inflammatory markers were significant down-regulation in both CCl4 and MCD induced liver fibrosis mice after Ficus hirta Vahl administration in a dose-dependent manner. We found that Ficus hirta Vahl may primarily exert its effect on liver fibrosis through the glutathione metabolic pathway. Importantly, the glutathione metabolic pathway is closely associated with ferroptosis, and our subsequent in vitro experiments provided evidence supporting this association. Ficus hirta Vahl was found to modulate the GSH/GPX4 pathway, ultimately leading to the amelioration of liver fibrosis. Moreover, using serum pharmacochemistry and molecular docking, we successfully identified apigenin as a probable efficacious monomer for the management of liver fibrosis and subsequently validated its efficacy in mice with CCl4-induced hepatic fibrosis. Conclusion: Ficus hirta Vahl triggered the ferroptosis of hepatic stellate cell by regulating the GSH/GPX4 pathway, thereby alleviating liver fibrosis in mice. Moreover, apigenin is a key compound in Ficus hirta Vahl responsible for the effective treatment of liver fibrosis.
引用
收藏
页数:12
相关论文
共 50 条
  • [1] Ficus hirta Vahl. Ameliorates Nonalcoholic Fatty Liver Disease through Regulating Lipid Metabolism and Gut Microbiota
    Quan, Ting
    Zhou, Fangyu
    Chen, Huiyuan
    Jian, Lina
    Yang, Yuxuan
    Xia, Fan
    Xiang, Shijian
    Zhou, Benjie
    Li, Shasha
    OXIDATIVE MEDICINE AND CELLULAR LONGEVITY, 2022, 2022
  • [2] Magnesium isoglycyrrhizinate ameliorates liver fibrosis and hepatic stellate cell activation by regulating ferroptosis signaling pathway
    Sui, Miao
    Jiang, Xiaofei
    Chen, Jun
    Yang, Haiyan
    Zhu, Yan
    BIOMEDICINE & PHARMACOTHERAPY, 2018, 106 : 125 - 133
  • [3] Dexmedetomidine ameliorates diabetic cardiomyopathy by inhibiting ferroptosis through the Nrf2/GPX4 pathway
    Li, Fan
    Hu, Zhenfei
    Huang, Yidan
    Zhan, Haiting
    JOURNAL OF CARDIOTHORACIC SURGERY, 2023, 18 (01)
  • [4] Esculin inhibits hepatic stellate cell activation and CCl4-induced liver fibrosis by activating the Nrf2/GPX4 signaling pathway
    Xu, Shuoxi
    Chen, Yonger
    Miao, Jindian
    Li, Yuhua
    Liu, Jiaying
    Zhang, Jing
    Liang, Jian
    Chen, Shuxian
    Hou, Shaozhen
    PHYTOMEDICINE, 2024, 128
  • [5] Dexmedetomidine ameliorates diabetic cardiomyopathy by inhibiting ferroptosis through the Nrf2/GPX4 pathway
    Fan Li
    Zhenfei Hu
    Yidan Huang
    Haiting Zhan
    Journal of Cardiothoracic Surgery, 18
  • [6] Ghrelin alleviates liver fibrosis by triggering HSCs ferroptosis via regulating injured hepatocyte-derived exosomal LncMALAT1/GPX4 pathway
    Luo, Xin
    Chen, Kan
    Zhang, Jie
    Yao, Zhilu
    Guo, Chuanyong
    Qu, Ying
    Lu, Lungen
    Mao, Yuqing
    FASEB JOURNAL, 2025, 39 (02):
  • [7] Sorafenib attenuates liver fibrosis by triggering hepatic stellate cell ferroptosis via HIF-1α/SLC7A11 pathway
    Yuan, Siyu
    Wei, Can
    Liu, Guofang
    Zhang, Lijun
    Li, Jiahao
    Li, Lingling
    Cai, Shiyi
    Fang, Ling
    CELL PROLIFERATION, 2022, 55 (01)
  • [8] Wogonoside attenuates liver fibrosis by triggering hepatic stellate cell ferroptosis through SOCS1/P53/SLC7A11 pathway
    Liu, Guofang
    Wei, Can
    Yuan, Siyu
    Zhang, Zhe
    Li, Jiahao
    Zhang, Lijun
    Wang, Guokai
    Fang, Ling
    PHYTOTHERAPY RESEARCH, 2022, 36 (11) : 4230 - 4243
  • [9] Xanthohumol ameliorates drug-induced hepatic ferroptosis via activating Nrf2/xCT/GPX4 signaling pathway
    Deng, Yanyan
    Chu, Xiayan
    Li, Qian
    Zhu, Guanghao
    Hu, Jing
    Sun, Jianming
    Zeng, Hairong
    Huang, Jian
    Ge, Guangbo
    PHYTOMEDICINE, 2024, 126
  • [10] Caveolin-1 ameliorates hepatic injury in non-alcoholic fatty liver disease by inhibiting ferroptosis via the NOX4/ROS/GPX4 pathway
    Wu, Shuai
    Guo, Ning
    Xu, Hanlin
    Li, Yu
    Sun, Tianyin
    Jiang, Xiangfu
    Fu, Dongdong
    You, Tingyu
    Diao, Shaoxi
    Huang, Yan
    Hu, Chengmu
    BIOCHEMICAL PHARMACOLOGY, 2024, 230